{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:29Z","timestamp":1760146649503,"version":"build-2065373602"},"reference-count":100,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>In recent years, the European market, including Romania, has witnessed a significant increase in the promotion of cannabidiol (CBD)-based products, often presented as effective treatments for various health conditions. This study investigates the inconsistencies between the health claims associated with these supplements and the evidence from clinical trials. To identify products available on the Romanian market, a systematic review of online pharmacies and websites that specialize in selling CBD-based products has been performed. Additionally, a systematic review of clinical trials has been conducted to assess the efficacy of CBD for the specified indications. Our analysis revealed that some claims, such as those related to post-traumatic stress disorder, lack substantial clinical evidence. Moreover, even when clinical support exists, the dosages recommended for the supplements are often significantly lower than those used in trials, raising concerns about their efficacy. These findings highlight the need for stricter regulatory oversight and more transparent communication to ensure that consumer expectations are aligned with scientific evidence, ultimately promoting informed decision-making and consumer safety.<\/jats:p>","DOI":"10.3390\/pharmacy12060176","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T05:21:32Z","timestamp":1732512092000},"page":"176","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cannabidiol Supplements in Romania: Bridging the Gap Between Marketed Claims and Clinical Reality"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1789-742X","authenticated-orcid":false,"given":"Corina","family":"Andrei","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-8052","authenticated-orcid":false,"given":"George Mihai","family":"Nitulescu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-3069","authenticated-orcid":false,"given":"Georgiana","family":"Nitulescu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-5082","authenticated-orcid":false,"given":"Anca","family":"Zanfirescu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guti\u00e9rrez, M.S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., and Manzanares, J. (2020). Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, 10.","DOI":"10.3390\/biom10111575"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Soria-Gomez, E., Metna, M., Bellocchio, L., Busquets-Garcia, A., and Marsicano, G. (2017). The Endocannabinoid System in the Control of Behavior. Handbook of Neurobehavioral Genetics and Phenotyping, Wiley.","DOI":"10.1002\/9781118540770.ch13"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s12035-018-1143-4","article-title":"Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex","volume":"56","author":"Sales","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"14083","DOI":"10.1096\/fj.202000975R","article-title":"A Molecular Basis for the Anti-Inflammatory and Anti-Fibrosis Properties of Cannabidiol","volume":"34","author":"Sunda","year":"2020","journal-title":"FASEB J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2147\/JPR.S258433","article-title":"CBD Effects on TRPV1 Signaling Pathways in Cultured DRG Neurons","volume":"13","author":"Anand","year":"2020","journal-title":"J. Pain Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"154771","DOI":"10.1016\/j.phymed.2023.154771","article-title":"Cannabidiol Goes Nuclear: The Role of PPAR\u03b3","volume":"114","author":"Khosropoor","year":"2023","journal-title":"Phytomedicine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1021\/acs.jmedchem.5b01812","article-title":"Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain","volume":"59","author":"Brindisi","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1007\/s11064-023-03983-z","article-title":"Capsaicin, The Vanilloid Receptor TRPV1 Agonist in Neuroprotection: Mechanisms Involved and Significance","volume":"48","year":"2023","journal-title":"Neurochem. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/BST0341341","article-title":"PPAR: A New Pharmacological Target for Neuroprotection in Stroke and Neurodegenerative Diseases","volume":"34","author":"Bordet","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/bs.irn.2024.05.002","article-title":"Therapeutic Potential of CBD in Autism Spectrum Disorder","volume":"177","author":"Pedrazzi","year":"2024","journal-title":"Int. Rev. Neurobiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.smrv.2020.101339","article-title":"Cannabinoid Therapies in the Management of Sleep Disorders: A Systematic Review of Preclinical and Clinical Studies","volume":"53","author":"Suraev","year":"2020","journal-title":"Sleep Med. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00213-021-05905-9","article-title":"Cannabidiol (CBD) as a Novel Treatment in the Early Phases of Psychosis","volume":"239","author":"Chesney","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_13","first-page":"33","article-title":"Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence","volume":"9","author":"Cata","year":"2015","journal-title":"Subst. Abus. Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Seltzer, E.S., Watters, A.K., MacKenzie, D., Granat, L.M., and Zhang, D. (2020). Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers, 12.","DOI":"10.3390\/cancers12113203"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Martini, S., Gemma, A., Ferrari, M., Cosentino, M., and Marino, F. (2023). Effects of Cannabidiol on Innate Immunity: Experimental Evidence and Clinical Relevance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043125"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102935","DOI":"10.1016\/j.drugpo.2020.102935","article-title":"Access to Cannabidiol Without a Prescription: A Cross-Country Comparison and Analysis","volume":"85","author":"McGregor","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"112600","DOI":"10.1016\/j.fct.2021.112600","article-title":"The Current Understanding of the Benefits, Safety, and Regulation of Cannabidiol in Consumer Products","volume":"157","author":"Li","year":"2021","journal-title":"Food Chem. Toxicol."},{"key":"ref_18","first-page":"485","article-title":"Emerging Use of Epidiolex (Cannabidiol) in Epilepsy","volume":"25","author":"Scutt","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"121575","DOI":"10.1016\/j.jns.2023.121575","article-title":"Seizure Outcomes with Cannabidiol (CBD) in Pediatric Versus Adult Patients with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS): Subgroup Analysis of Become, a Caregiver Survey","volume":"455","author":"Saurer","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Boivin, M. (2021). Nabiximols (Sativex\u00ae). Cannabinoids and Pain, Springer International Publishing.","DOI":"10.1007\/978-3-030-69186-8_17"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Melas, P.A., Scherma, M., Fratta, W., Cifani, C., and Fadda, P. (2021). Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041863"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.31887\/DCNS.2020.22.3\/rmaldonado","article-title":"The Endocannabinoid System in Modulating Fear, Anxiety, and Stress","volume":"22","author":"Maldonado","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic Properties of Cannabidiol at 5-HT1a Receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18-041","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in Anxiety and Sleep: A Large Case Series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"21m14130","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People","volume":"83","author":"Berger","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zuardi, A.W., Rodrigues, N.P., Silva, A.L., Bernardo, S.A., Hallak, J.E.C., Guimar\u00e3es, F.S., and Crippa, J.A.S. (2017). Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00259"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1089\/can.2022.0062","article-title":"A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students","volume":"8","author":"Stanley","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Na\u00efve Social Phobia Patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report","volume":"25","author":"Crippa","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Masataka, N. (2019). Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers with Social Anxiety Disorders. Front. Psychol., 10.","DOI":"10.3389\/fpsyg.2019.02466"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00213-023-06437-0","article-title":"The Effects of Cannabidiol on Worry and Anxiety Among High Trait Worriers: A Double-Blind, Randomized Placebo Controlled Trial","volume":"240","author":"Gournay","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of Acute Cannabidiol Administration on Anxiety and Tremors Induced by a Simulated Public Speaking Test in Patients with Parkinson\u2019s Disease","volume":"34","author":"Tumas","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Parrella, N.-F., Hill, A.T., Enticott, P.G., Botha, T., Catchlove, S., Downey, L., and Ford, T.C. (2024). Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomised Controlled Crossover Trial. medRxiv.","DOI":"10.1101\/2024.06.19.24309024"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00213-021-06043-y","article-title":"Effects of Cannabidiol on Symptoms Induced by the Recall of Traumatic Events in Patients with Posttraumatic Stress Disorder","volume":"239","author":"Bolsoni","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1590\/1516-4446-2021-2317","article-title":"The Anxiolytic Effect of Cannabidiol Depends on the Nature of the Trauma When Patients with Post-Traumatic Stress Disorder Recall Their Trigger Event","volume":"44","author":"Bolsoni","year":"2022","journal-title":"Braz. J. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106933","DOI":"10.1016\/j.cct.2022.106933","article-title":"Use of Cannabidiol (CBD) Oil in the Treatment of PTSD: Study Design and Rationale for a Placebo-Controlled Randomized Clinical Trial","volume":"122","author":"Telch","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"052908","DOI":"10.1155\/2007\/52908","article-title":"Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses","volume":"2007","author":"Viveros","year":"2007","journal-title":"Neural Plast."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Foga\u00e7a, M.V., Campos, A.C., and Guimar\u00e3es, F.S. (2016). Cannabidiol and 5-HT1A Receptors. Neuropathology of Drug Addictions and Substance Misuse, Elsevier.","DOI":"10.1016\/B978-0-12-800213-1.00070-5"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Zhao, F., Zhang, H., Wang, P., Cui, W., Xu, K., Chen, D., Hu, M., Li, Z., Geng, X., and Wei, S. (2022). Oxytocin and Serotonin in the Modulation of Neural Function: Neurobiological Underpinnings of Autism-Related Behavior. Front. Neurosci., 16.","DOI":"10.3389\/fnins.2022.919890"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.neubiorev.2020.12.009","article-title":"Healing Autism Spectrum Disorder with Cannabinoids: A Neuroinflammatory Story","volume":"121","author":"Carbone","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Barchel, D., Stolar, O., De-Haan, T., Ziv-Baran, T., Saban, N., Fuchs, D.O., Koren, G., and Berkovitch, M. (2019). Oral Cannabidiol Use in Children with Autism Spectrum Disorder to Treat Related Symptoms and Co-Morbidities. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01521"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13256-020-02478-7","article-title":"A Pediatric Patient with Autism Spectrum Disorder and Epilepsy Using Cannabinoid Extracts as Complementary Therapy: A Case Report","volume":"14","author":"Ponton","year":"2020","journal-title":"J. Med. Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s42238-021-00108-7","article-title":"CBD-Enriched Cannabis for Autism Spectrum Disorder: An Experience of a Single Center in Turkey and Reviews of the Literature","volume":"3","author":"Bilge","year":"2021","journal-title":"J. Cannabis Res."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fleury-Teixeira, P., Caixeta, F.V., da Silva, L.C.R., Brasil-Neto, J.P., and Malcher-Lopes, R. (2019). Effects of CBD-Enriched Cannabis Sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.01145"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2174\/13816128113199990432","article-title":"Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: A Systematic Review","volume":"20","author":"Batalla","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-019-0333-8","article-title":"Effects of Cannabidiol on Brain Excitation and Inhibition Systems; a Randomised Placebo-Controlled Single Dose Trial During Magnetic Resonance Spectroscopy in Adults with and Without Autism Spectrum Disorder","volume":"44","author":"Pretzsch","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/0269881119858306","article-title":"The Effect of Cannabidiol (CBD) on Low-Frequency Activity and Functional Connectivity in the Brain of Adults with and Without Autism Spectrum Disorder (ASD)","volume":"33","author":"Pretzsch","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/bcp.14399","article-title":"A Pilot Randomised Placebo-controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents with Intellectual Disability","volume":"87","author":"Efron","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Mlost, J., Bryk, M., and Starowicz, K. (2020). Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228870"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3934\/Neuroscience.2024009","article-title":"A Review of the Direct Targets of the Cannabinoids Cannabidiol, \u03949-Tetrahydrocannabinol, N-Arachidonoylethanolamine and 2-Arachidonoylglycerol","volume":"11","author":"Wright","year":"2024","journal-title":"AIMS Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s40265-022-01685-4","article-title":"From a Symptom-Based to a Mechanism-Based Pharmacotherapeutic Treatment in Complex Regional Pain Syndrome","volume":"82","author":"Mangnus","year":"2022","journal-title":"Drugs"},{"key":"ref_52","first-page":"e67224","article-title":"Cannabidiol for the Treatment of Cervical Spondyloarthritis-Related Pain: A Case Report","volume":"16","author":"Tadei","year":"2024","journal-title":"Cureus"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/imr.2023.0002","article-title":"Full-Spectrum Cannabidiol for Treating Chronic Temporomandibular Arthralgia: A Case Report","volume":"2","author":"Tanganeli","year":"2023","journal-title":"Integr. Med. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"23259671231222265","DOI":"10.1177\/23259671231222265","article-title":"Cannabidiol for Postoperative Pain Control After Arthroscopic Rotator Cuff Repair Demonstrates No Deficits in Patient-Reported Outcomes Versus Placebo: 1-Year Follow-Up of a Randomized Controlled Trial","volume":"12","author":"Alaia","year":"2024","journal-title":"Orthop. J. Sports Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2044.2004.03674.x","article-title":"Initial Experiences with Medicinal Extracts of Cannabis for Chronic Pain: Results from 34 \u2018N of 1\u2032 Studies","volume":"59","author":"Notcutt","year":"2004","journal-title":"Anaesthesia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/j.pain.0000000000002466","article-title":"Cannabidiol Treatment in Hand Osteoarthritis and Psoriatic Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"163","author":"Vela","year":"2022","journal-title":"Pain"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5694\/mja2.51014","article-title":"The CANBACK Trial: A Randomised, Controlled Clinical Trial of Oral Cannabidiol for People Presenting to the Emergency Department with Acute Low Back Pain","volume":"214","author":"Bebee","year":"2021","journal-title":"Med. J. Aust."},{"key":"ref_58","first-page":"100777","article-title":"Oral Cannabidiol (CBD) as Add-On to Paracetamol for Painful Chronic Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"35","author":"Pramhas","year":"2023","journal-title":"Lancet Reg. Health"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/ejp.2072","article-title":"Oral Capsules of Tetra-Hydro-Cannabinol (THC), Cannabidiol (CBD) and Their Combination in Peripheral Neuropathic Pain Treatment","volume":"27","author":"Zubcevic","year":"2023","journal-title":"Eur. J. Pain"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"108325","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure Frequency, Quality of Life, Behavior, Cognition, and Sleep in Pediatric Patients Enrolled in a Prospective, Open-Label Clinical Study with Cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/acm.2018.0437","article-title":"Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series","volume":"25","author":"Elms","year":"2019","journal-title":"J. Altern. Complement. Med."},{"key":"ref_62","first-page":"1","article-title":"The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial","volume":"43","author":"Saleska","year":"2024","journal-title":"J. Am. Nutr. Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Wang, M., Faust, M., Abbott, S., Patel, V., Chang, E., Clark, J.I., Stella, N., and Muchowski, P.J. (2024). Effects of a Cannabidiol\/Terpene Formulation on Sleep in Individuals with Insomnia: A Double-Blind, Placebo-Controlled, Randomized, Crossover Study. J. Clin. Sleep Med.","DOI":"10.5664\/jcsm.11324"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5664\/jcsm.10998","article-title":"Cannabidiol for Moderate\u2013Severe Insomnia: A Randomized Controlled Pilot Trial of 150 Mg of Nightly Dosing","volume":"20","author":"Narayan","year":"2024","journal-title":"J. Clin. Sleep Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","article-title":"Cannabidiol as a Potential Treatment for Psychosis","volume":"24","author":"Schubart","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Batalla, A., Janssen, H., Gangadin, S.S., and Bossong, M.G. (2019). The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8071058"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of Schizophrenic Patients in the Stroop Color Word Test and Electrodermal Responsiveness After Acute Administration of Cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Rev. Bras. Psiquiatr."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0269881117737400","article-title":"The Effects of Cannabidiol on Persecutory Ideation and Anxiety in a High Trait Paranoid Group","volume":"32","author":"Hundal","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The Effects of Cannabidiol (CBD) on Cognition and Symptoms in Outpatients with Chronic Schizophrenia a Randomized Placebo Controlled Trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pbb.2005.01.032","article-title":"Endocannabinoid Signaling System and Brain Reward: Emphasis on Dopamine","volume":"81","author":"Gardner","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol Is an Allosteric Modulator at Mu- and Delta-Opioid Receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Karimi-Haghighi, S., Dargahi, L., and Haghparast, A. (2020). Cannabidiol Modulates the Expression of Neuroinflammatory Factors in Stress- and Drug-Induced Reinstatement of Methamphetamine in Extinguished Rats. Addict. Biol., 25.","DOI":"10.1111\/adb.12740"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brainresbull.2021.04.007","article-title":"Cannabidiol Modulates the METH-Induced Conditioned Place Preference Through D2-Like Dopamine Receptors in the Hippocampal CA1 Region","volume":"172","author":"Hassanlou","year":"2021","journal-title":"Brain Res. Bull."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral Cannabidiol Does Not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the Treatment of Cannabis Use Disorder: A Phase 2a, Double-Blind, Placebo-Controlled, Randomised, Adaptive Bayesian Trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","article-title":"Cannabidiol for the Treatment of Crack-Cocaine Craving: An Exploratory Double-Blind Study","volume":"43","author":"Crippa","year":"2021","journal-title":"Braz. J. Psychiatry"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol Reduces Cigarette Consumption in Tobacco Smokers: Preliminary Findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict. Behav."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00213-022-06303-5","article-title":"Effect of Four-Week Cannabidiol Treatment on Cognitive Function: Secondary Outcomes from a Randomised Clinical Trial for the Treatment of Cannabis Use Disorder","volume":"240","author":"Lees","year":"2023","journal-title":"Psychopharmacology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals with Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101341","DOI":"10.1016\/j.conctc.2024.101341","article-title":"The Neurobehavioural Effects of Cannabidiol in Alcohol Use Disorder: Study Protocol for a Double-Blind, Randomised, Cross Over, Placebo-Controlled Trial","volume":"41","author":"Hurzeler","year":"2024","journal-title":"Contemp. Clin. Trials Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/ADM.0000000000000959","article-title":"Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals with Cocaine Use Disorder: Exploratory Results from a Randomized Controlled Trial","volume":"16","author":"Rizkallah","year":"2022","journal-title":"J. Addict. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/add.14243","article-title":"Cannabidiol Reverses Attentional Bias to Cigarette Cues in a Human Experimental Model of Tobacco Withdrawal","volume":"113","author":"Hindocha","year":"2018","journal-title":"Addiction"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clim.2006.11.002","article-title":"CB2 Cannabinoid Receptor Agonist, JWH-015, Triggers Apoptosis in Immune Cells: Potential Role for CB2-Selective Ligands as Immunosuppressive Agents","volume":"122","author":"Lombard","year":"2007","journal-title":"Clin. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cellimm.2016.11.006","article-title":"Cannabidiol (CBD) Induces Functional Tregs in Response to Low-Level T Cell Activation","volume":"312","author":"Dhital","year":"2017","journal-title":"Cell. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bcp.2008.06.022","article-title":"The Profile of Immune Modulation by Cannabidiol (CBD) Involves Deregulation of Nuclear Factor of Activated T Cells (NFAT)","volume":"76","author":"Kaplan","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1089\/can.2023.0039","article-title":"Cannabidiol Reduces Systemic Immune Activation in Experimental Acute Lung Injury","volume":"9","author":"Hall","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10620-017-4540-z","article-title":"Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn\u2019s Disease, a Randomized Controlled Trial","volume":"62","author":"Naftali","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ibd\/izy002","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Pilot Study of Cannabidiol-Rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis","volume":"24","author":"Irving","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Heider, C.G., Itenberg, S.A., Rao, J., Ma, H., and Wu, X. (2022). Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review. Biology, 11.","DOI":"10.3390\/biology11060817"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bcpt.13710","article-title":"A Narrative Review of Molecular Mechanism and Therapeutic Effect of Cannabidiol (CBD)","volume":"130","author":"Peng","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.21873\/anticanres.12924","article-title":"Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-Grade Synthetic Cannabidiol","volume":"38","author":"Kenyon","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/jpm.2019.0540","article-title":"An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care","volume":"23","author":"Good","year":"2020","journal-title":"J. Palliat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Good, P., Haywood, A., Gogna, G., Martin, J., Yates, P., Greer, R., and Hardy, J. (2019). Oral Medicinal Cannabinoids to Relieve Symptom Burden in the Palliative Care of Patients with Advanced Cancer: A Double-Blind, Placebo Controlled, Randomised Clinical Trial of Efficacy and Safety of Cannabidiol (CBD). BMC Palliat. Care, 18.","DOI":"10.1186\/s12904-019-0494-6"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.22.01632","article-title":"Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD)","volume":"41","author":"Hardy","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain","volume":"39","author":"Johnson","year":"2010","journal-title":"J. Pain. Symptom Manag."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","article-title":"Oral THC:CBD Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting: A Randomised, Placebo-Controlled, Phase II Crossover Trial","volume":"31","author":"Grimison","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s43856-022-00202-8","article-title":"Clinical and Cognitive Improvement Following Full-Spectrum, High-Cannabidiol Treatment for Anxiety: Open-Label Data from a Two-Stage, Phase 2 Clinical Trial","volume":"2","author":"Dahlgren","year":"2022","journal-title":"Commun. Med."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/6\/176\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:38:39Z","timestamp":1760114319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/6\/176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":100,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["pharmacy12060176"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy12060176","relation":{},"ISSN":["2226-4787"],"issn-type":[{"type":"electronic","value":"2226-4787"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}